E
CNCE

Ergoteles’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Ergoteles’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-126,838
Closed -$415K – 1719
2021
Q3 		$415K Buy
126,838
+3,681
+3% +$12.9K 0.02% 666
2021
Q2 		$520K Buy
+123,157
New +$521K 0.01% 786

Other funds holding CNCE

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ergoteles's CNCE Position: Q4 2021 in Review

Ergoteles sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q4 2021, closing a stake of 126,838 shares — an estimated $415K sold.

Ergoteles first reported a position in CNCE in Q2 2021 and held it in 2 quarters. The position peaked at $520K in Q2 2021. 52 funds tracked by Wall St. Rank hold CNCE as of Q4 2021.

  • Ergoteles reported no remaining Concert Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
  • Ergoteles sold 126,838 Concert Pharmaceuticals, Inc. shares in Q4 2021, an estimated $415K.
  • Ergoteles first reported a position in Concert Pharmaceuticals, Inc. in Q2 2021 and held it in 2 quarters.
  • Ergoteles's Concert Pharmaceuticals, Inc. position peaked at $520K in Q2 2021.
  • 52 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q4 2021.

Based on Ergoteles's 13F filing for Q4 2021, filed 14 Feb 2022.